RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Abstract Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti‐tumour immunity but not every form of death can elicit an immune response. Moreover, resistance to apoptosis is a major problem in ca...
Main Authors: | Henry G Smith, Kunzah Jamal, Jasbani HS Dayal, Tencho Tenev, Joan Kyula‐Currie, Naomi Guppy, Patrycja Gazinska, Victoria Roulstone, Gianmaria Liccardi, Emma Davies, Ioannis Roxanis, Alan A Melcher, Andrew J Hayes, Gareth J Inman, Kevin J Harrington, Pascal Meier |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2020-06-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201910979 |
Similar Items
-
Future Therapeutic Directions for Smac-Mimetics
by: Emma Morrish, et al.
Published: (2020-02-01) -
The TwistDock workflow for evaluation of bivalent Smac mimetics targeting XIAP
by: Huang Q, et al.
Published: (2019-04-01) -
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
by: Brianna M. Craver, et al.
Published: (2020-01-01) -
The Role of RIPK1 and RIPK3 in Cardiovascular Disease
by: Elise DeRoo, et al.
Published: (2020-10-01) -
Natural Flavonoids Quercetin and Kaempferol Targeting G2/M Cell Cycle-Related Genes and Synergize with Smac Mimetic LCL-161 to Induce Necroptosis in Cholangiocarcinoma Cells
by: Thanpisit Lomphithak, et al.
Published: (2023-07-01)